FRESENIUS MEDICAL CARE AG Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used
FRESENIUS MEDICAL CARE AG (FMCQF) reported Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used of EUR 65.21 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed · last filed 2026-02-24
- FRESENIUS MEDICAL CARE AG expense relating to shortterm leases for which recognition exemption has been used for the quarter ending 2019-12-31 was 12.57M EUR.
- FRESENIUS MEDICAL CARE AG expense relating to shortterm leases for which recognition exemption has been used for the quarter ending 2019-09-30 was 17.05M EUR.
- FRESENIUS MEDICAL CARE AG expense relating to shortterm leases for which recognition exemption has been used for the quarter ending 2019-06-30 was 10.28M EUR.
- FRESENIUS MEDICAL CARE AG expense relating to shortterm leases for which recognition exemption has been used for the quarter ending 2019-03-31 was 12.21M EUR.
| Period end | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 3 month | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 6 month | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 9 month | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 12 month |
|---|---|---|---|---|
| 2025-12-31 | 65.21M EUR 20-F · filed 2026-02-24 | |||
| 2024-12-31 | 53.06M EUR 20-F · filed 2026-02-24 | |||
| 2023-12-31 | 59.33M EUR 20-F · filed 2026-02-24 | |||
| 2022-12-31 | 52.42M EUR 20-F · filed 2025-02-25 | |||
| 2021-12-31 | 44.92M EUR 20-F · filed 2024-02-20 | |||
| 2020-12-31 | 49.53M EUR 20-F · filed 2023-02-22 | |||
| 2019-12-31 | 12.57M EUR derived: 20-F 12 month − 6-K 9 month · filed 2022-02-22 | 29.61M EUR derived: sum of 2 quarters · filed 2022-02-22 | 39.90M EUR derived: sum of 3 quarters · filed 2022-02-22 | 52.11M EUR 20-F · filed 2022-02-22 |
| 2019-09-30 | 17.05M EUR 6-K · filed 2019-10-31 | 27.33M EUR derived: sum of 2 quarters · filed 2019-10-31 | 39.54M EUR 6-K · filed 2019-10-31 | |
| 2019-06-30 | 10.28M EUR 6-K · filed 2019-07-30 | 22.49M EUR 6-K · filed 2019-07-30 | ||
| 2019-03-31 | 12.21M EUR 6-K · filed 2019-05-02 |